Patrick Carriere , Omar Alhalabi , Jianjun Gao , Osama Mohamad , Matthew T. Campbell , Amishi Shah , Sangeeta Goswami , Kelly Bree , Byron Lee , Neema Navai , Henry Mok , Lauren Mayo , Charles Guo , Quynh Nguyen , Sean McGuire , Ryan Park , Shalin Shah , Karen Hoffman , Steven Frank , Chad Tang , Comron Hassanzadeh
{"title":"为局部晚期和结节阳性膀胱癌患者提供保留膀胱的放射治疗","authors":"Patrick Carriere , Omar Alhalabi , Jianjun Gao , Osama Mohamad , Matthew T. Campbell , Amishi Shah , Sangeeta Goswami , Kelly Bree , Byron Lee , Neema Navai , Henry Mok , Lauren Mayo , Charles Guo , Quynh Nguyen , Sean McGuire , Ryan Park , Shalin Shah , Karen Hoffman , Steven Frank , Chad Tang , Comron Hassanzadeh","doi":"10.1016/j.ctro.2024.100866","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explored our experience with LA-MIBC undergoing radiation therapy (RT).</div></div><div><h3>Methods</h3><div>We retrospectively identified 30 patients from an institutional prospectively collated database with non-metastatic, LA-MIBC. Patients with T3-4 N0 or T2-4 N + treated from 2012 to 2022 with definitive-intent RT, who were not candidates for cystectomy were included. Kaplan-Meier analysis was used to estimate time-to-event outcomes, and multivariate analyses were conducted using Cox proportional hazards modeling.</div></div><div><h3>Results</h3><div>43 % had T3N0 disease, 30 % had T4N0 disease, and 27 % had node positive disease.. Neoadjuvant chemotherapy/systemic therapy was administered in 63 % of patients. Median dose and fractionation of RT was 60 Gy in 30 fractions. 23 % of patients received hypofractionated RT, 57 % received nodal RT.</div><div>At a median follow-up of 20 (range, 1–75) months after RT, estimated 1- and 2-year OS was 73 % and 61 %, respectively. Estimated 1-year progression-free survival was 50 %. Local bladder failure was a component of progression in 17 % of patients, and all local bladder failure events occurred within the first 12 months following RT. Lymph node or distant metastases occurred in 23 % of patients. Estimated 1-year OS was 83 % with pure urothelial histology but only 58 % with variant histology (P = 0.001). Late grade 3 + GU and GI toxicity occurred in 7 % and 5 % of patients, respectively.</div></div><div><h3>Conclusions</h3><div>In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation is warranted to identify biomarkers for patient selection and strategies to improve distant control.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"49 ","pages":"Article 100866"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer\",\"authors\":\"Patrick Carriere , Omar Alhalabi , Jianjun Gao , Osama Mohamad , Matthew T. Campbell , Amishi Shah , Sangeeta Goswami , Kelly Bree , Byron Lee , Neema Navai , Henry Mok , Lauren Mayo , Charles Guo , Quynh Nguyen , Sean McGuire , Ryan Park , Shalin Shah , Karen Hoffman , Steven Frank , Chad Tang , Comron Hassanzadeh\",\"doi\":\"10.1016/j.ctro.2024.100866\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explored our experience with LA-MIBC undergoing radiation therapy (RT).</div></div><div><h3>Methods</h3><div>We retrospectively identified 30 patients from an institutional prospectively collated database with non-metastatic, LA-MIBC. Patients with T3-4 N0 or T2-4 N + treated from 2012 to 2022 with definitive-intent RT, who were not candidates for cystectomy were included. Kaplan-Meier analysis was used to estimate time-to-event outcomes, and multivariate analyses were conducted using Cox proportional hazards modeling.</div></div><div><h3>Results</h3><div>43 % had T3N0 disease, 30 % had T4N0 disease, and 27 % had node positive disease.. Neoadjuvant chemotherapy/systemic therapy was administered in 63 % of patients. Median dose and fractionation of RT was 60 Gy in 30 fractions. 23 % of patients received hypofractionated RT, 57 % received nodal RT.</div><div>At a median follow-up of 20 (range, 1–75) months after RT, estimated 1- and 2-year OS was 73 % and 61 %, respectively. Estimated 1-year progression-free survival was 50 %. Local bladder failure was a component of progression in 17 % of patients, and all local bladder failure events occurred within the first 12 months following RT. Lymph node or distant metastases occurred in 23 % of patients. Estimated 1-year OS was 83 % with pure urothelial histology but only 58 % with variant histology (P = 0.001). Late grade 3 + GU and GI toxicity occurred in 7 % and 5 % of patients, respectively.</div></div><div><h3>Conclusions</h3><div>In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation is warranted to identify biomarkers for patient selection and strategies to improve distant control.</div></div>\",\"PeriodicalId\":10342,\"journal\":{\"name\":\"Clinical and Translational Radiation Oncology\",\"volume\":\"49 \",\"pages\":\"Article 100866\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405630824001435\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630824001435","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的对于经过适当选择的患者,肌层浸润性膀胱癌(MIBC)的三联疗法与根治性膀胱切除术相比,可获得相似的肿瘤治疗效果;然而,有关局部晚期肌层浸润性膀胱癌(LA-MIBC)的数据却很有限。我们探讨了接受放射治疗(RT)的 LA-MIBC 患者的经验。我们纳入了2012年至2022年期间接受确定性RT治疗的T3-4 N0或T2-4 N +患者,这些患者不适合接受膀胱切除术。采用Kaplan-Meier分析法估算从时间到事件的结果,并采用Cox比例危险模型进行多变量分析。结果43%的患者病情为T3N0,30%的患者病情为T4N0,27%的患者病情为结节阳性。63%的患者接受了新辅助化疗/系统治疗。RT的中位剂量和分次剂量为60 Gy,分30次进行。23%的患者接受了低分量RT,57%的患者接受了结节RT。RT治疗后的中位随访时间为20个月(1-75个月),估计1年和2年的OS分别为73%和61%。估计1年无进展生存率为50%。局部膀胱功能衰竭是17%患者病情进展的一个因素,所有局部膀胱功能衰竭事件都发生在RT术后的前12个月内。23%的患者出现淋巴结或远处转移。纯尿路上皮组织学患者的估计 1 年 OS 为 83%,而变异组织学患者仅为 58%(P = 0.001)。结论 在这组接受 RT 治疗的 LA-MIBC 患者中,远处治疗失败者居多,局部治疗失败者较少,且毒性很小。在这一具有挑战性的患者群体中,RT的生存结果仍然令人鼓舞。有必要进行进一步研究,以确定选择患者的生物标志物和改善远处控制的策略。
Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer
Purpose
Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explored our experience with LA-MIBC undergoing radiation therapy (RT).
Methods
We retrospectively identified 30 patients from an institutional prospectively collated database with non-metastatic, LA-MIBC. Patients with T3-4 N0 or T2-4 N + treated from 2012 to 2022 with definitive-intent RT, who were not candidates for cystectomy were included. Kaplan-Meier analysis was used to estimate time-to-event outcomes, and multivariate analyses were conducted using Cox proportional hazards modeling.
Results
43 % had T3N0 disease, 30 % had T4N0 disease, and 27 % had node positive disease.. Neoadjuvant chemotherapy/systemic therapy was administered in 63 % of patients. Median dose and fractionation of RT was 60 Gy in 30 fractions. 23 % of patients received hypofractionated RT, 57 % received nodal RT.
At a median follow-up of 20 (range, 1–75) months after RT, estimated 1- and 2-year OS was 73 % and 61 %, respectively. Estimated 1-year progression-free survival was 50 %. Local bladder failure was a component of progression in 17 % of patients, and all local bladder failure events occurred within the first 12 months following RT. Lymph node or distant metastases occurred in 23 % of patients. Estimated 1-year OS was 83 % with pure urothelial histology but only 58 % with variant histology (P = 0.001). Late grade 3 + GU and GI toxicity occurred in 7 % and 5 % of patients, respectively.
Conclusions
In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation is warranted to identify biomarkers for patient selection and strategies to improve distant control.